Alector, Inc.

Good afternoon, ladies and gentlemen, and welcome to Electora fourth quarter and full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you would need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this conference is being recorded. I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Thank you, Operator, and hello, everyone. Earlier this afternoon, we released our financial results for the fourth quarter and full year 2024. The press release is available on our website at www.elector.com, and our 10-K was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, co-founder and CEO, Dr. Sarah Kankari Mitra, President and Head of Research and Development, Dr. Gary Romano, Chief Medical Officer, and Dr. Mark Grasso, Chief Financial Officer. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we'll be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statement disclosure. And we also encourage you to review our SEC filings for more information. I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?

Thank you, Katie. Good afternoon, everyone. And thank you for joining Elector's first quarter and full year 2024 financial results conference call. I'd like to begin by outlining our strategic direction guiding Elector forward and the opportunities that lie ahead. We are focused on discovering and developing first or best-in-class disease-modifying therapies for neurodegenerative disorders. such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease with high unmet medical needs, but effective medicines are urgently required. To achieve this, we continue to build an integrated biotechnology organization that combines deep expertise in genetics, immunology, and neuroscience with extensive drug discovery, protein engineering, and manufacturing. as well as clinical development and regulatory capability. We pursue therapies that target the underlying mechanisms of neurodegeneration, such as toxic misfolded proteins, deficient proteins, and dysfunction in immune, lysosomal, and neuronal systems. Our portfolio includes two first-in-class, late-stage clinical programs developed in collaboration with GSK, along with five discovery programs encompassing antibodies, enzymes, and nucleic acids, addressing both novel and more established targets. Central to our program is Alecto Brain Carrier, or ABC, our proprietary and versatile blood-brain barrier platform. ABC aims to enhance the delivery of our protein and nucleic acid therapeutics to the brain to improve efficacy and increase safety at lower doses and costs. We are advancing our wholly owned ABC-based programs and expect to be in the clinic in 2026. We anticipate realizing a significant portion of the company's potential in 2025. The readout of our pivotal phase three trial in frontotemporal dementia with progranulin gene mutation is planned for later this year. Additionally, we expect to complete patient recruitment for PROGRESS-AD, our phase two trial of AL-101 in early Alzheimer's disease. Beyond these initiatives, we are also advancing our preclinical pipeline, which Sarah will discuss later today. Throughout this process, we remain committed to making data-driven decisions that create sustainable value. With that, I'll turn the call over to Gary to discuss our goals and expectations for our clinical development programs. Gary?